2021
Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States
Parikh RB, Takvorian SU, Vader D, Wileyto E, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA, Investigators T. Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. Journal Of The National Cancer Institute 2021, 114: 571-578. PMID: 34893865, PMCID: PMC9002283, DOI: 10.1093/jnci/djab225.Peer-Reviewed Original ResearchConceptsMetastatic solid cancersFirst-line systemic therapyTreatment initiationSolid cancersSystemic therapyTreatment patternsMyelosuppressive therapyTreatment selectionCommunity-based oncology practicesCOVID-19 pandemicTechnology-enabled abstractionDays of diagnosisLife-threatening conditionInterrupted time series analysisMetastatic diagnosisUS patientsEffect modificationOncology practiceMetastatic cancerAdjusted probabilityPatientsPandemic periodPandemic-related delaysTherapyCancerRacial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database
Calip G, Ascha M, Wang X, Pierre A, Maignan K, Wadé N, Leng S, Seymour E, Chiu B, Sweiss K, Patel P, Neparidze N. Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database. Blood 2021, 138: 4121. DOI: 10.1182/blood-2021-152774.Peer-Reviewed Original ResearchReal-world progression-free survivalHigh-risk cytogenetic abnormalitiesCurrent equity holderFlatiron HealthBlack patientsWhite patientsMultiple myelomaMM patientsCytogenetic abnormalitiesClinical characteristicsHazard ratioAge groupsAutologous stem cell transplantationAdvisory CommitteeAdult MM patientsCytogenetic risk stratificationOlder black patientsTechnology-enabled abstractionYoung black patientsAdjusted hazard ratioRetrospective cohort studyFirst-line therapyFirst-line treatmentHigh-risk subsetProgression-free survivalHow did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2020
A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.
Lu M, Walia G, Schulze K, Doral M, Maund S, Gaffey S, Cabili M, Bourla A, Green R, Santos E, Herbst R, Chiang A, Schwartzberg L. A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. Journal Of Clinical Oncology 2020, 38: tps2087-tps2087. DOI: 10.1200/jco.2020.38.15_suppl.tps2087.Peer-Reviewed Original ResearchCell lung cancerLung cancerOverall survivalOutcome dataExtensive-stage small-cell lung cancerMetastatic non-small cell lung cancerNon-small cell lung cancerSmall cell lung cancerReal-world clinical outcomesGenomic profilingFirst tumor assessmentFlatiron Health networkTechnology-enabled abstractionLines of therapyMetastatic lung cancerEnd of treatmentWithdrawal of consentClinical data pointsEnd of studyTumor DNA ProfilingAnti-neoplastic treatmentCase report formsTumor tissue samplesBlood genomic profilingElectronic health records
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply